title: Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors.
abstract: A study based on data from the French national health insurance system, for the period 2003-2011, has shown that patients with Alzheimer's disease receiving a cholinesterase inhibitor were exposed to another drug that reduces the heart rate in about 44% of cases, a neuroleptic in 33% of cases, and an antimuscarinic for urinary problems in 8% of cases. Drugs for Alzheimer's disease expose patients to dangerous drug-drug interactions.
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000009:adverse effects*; D004347:Drug Interactions; D005602:France; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects; D018579:Patient Selection; D019338:Polypharmacy; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D018727:Muscarinic Antagonists